Three Seasons Wealth LLC Invests $819,000 in Roivant Sciences Ltd. $ROIV

Three Seasons Wealth LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,557 shares of the company’s stock, valued at approximately $819,000.

Several other institutional investors also recently added to or reduced their stakes in ROIV. UBS Group AG grew its position in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after acquiring an additional 15,645,836 shares during the period. Morgan Stanley increased its stake in shares of Roivant Sciences by 31.7% during the 4th quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after purchasing an additional 14,036,696 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after purchasing an additional 8,621,567 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Roivant Sciences by 11,507.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock worth $150,535,000 after purchasing an additional 6,877,348 shares during the period. Finally, Norges Bank purchased a new position in Roivant Sciences in the fourth quarter valued at approximately $112,750,000. Institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ROIV. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Citigroup boosted their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. TD Cowen upped their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Insider Activity

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at $473,388,414.30. The trade was a 5.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 2,055,913 shares of company stock worth $68,567,633. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Trading Down 0.1%

ROIV opened at $34.89 on Thursday. Roivant Sciences Ltd. has a 12 month low of $10.90 and a 12 month high of $37.00. The company has a market cap of $25.10 billion, a PE ratio of -58.15 and a beta of 1.11. The company has a 50 day moving average of $31.45 and a 200 day moving average of $28.04.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the previous year, the firm posted ($0.29) EPS. Research analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.